Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma.

Blood cancer journal - 17 Apr 2025

Larocca Cecilia, Bui Ai-Tram N, O'Malley John T, Giobbie-Hurder Anita, Tawa Marianne, Teague Jessica E, Clark Rachael A, Cutler Corey, Jacobsen Eric, Fisher David C, Kupper Thomas S, LeBoeuf Nicole R

Abstract excerpt

Cutaneous T-cell lymphomas (CTCL) have in common malignant T-lymphocyte infiltration in the skin. Low dose alemtuzumab (LDA) appears to be an effective treatment for leukemic disease, but in the absence of clinical trials, there is need for improved characterization of patients with CTCL most likely to benefit. A retrospective cohort study of 38 patients with CTCL treated with LDA with at least 5 years' follow-up...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Follow-Up Studies

Share to Lymphoma, T-Cell, Cutaneous

Share to Phenotype

Share to Skin Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 40246811
DOI: 10.1038/s41408-025-01237-5
PMCID: PMC12006509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma.PMID 40246811Read ↗

Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.Semantic proximity Read ↗

Naïve/memory T‐cell phenotypes in leukemic cutaneous T‐cell lymphoma: Putative cell of origin overlaps disease classificationSemantic proximity Read ↗

Phenotypic Variability in Primary Cutaneous Anaplastic Large T-cell LymphomaSemantic proximity Read ↗

Primary cutaneous T-cell lymphoma of unspecified type with cytotoxic phenotype: clinicopathological analysis of 27 patients.Semantic proximity Read ↗

Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.Semantic proximity Read ↗

Cutaneous Lymphomas with Cytotoxic Phenotype.Semantic proximity Read ↗

Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.Semantic proximity Read ↗

Primary cutaneous T-cell lymphoma, unspecified, exhibiting an aggressive clinical course and a cytotoxic phenotype.Semantic proximity Read ↗

Cutaneous large cell lymphomas of T cell origin: diagnosis, classification and prognostic parameters.Semantic proximity Read ↗

CD8-positive primary cutaneous peripheral T-cell lymphoma, unspecified.Semantic proximity Read ↗

Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.Semantic proximity Read ↗

Unique Presentation of Leukemic Cutaneous CD3/TCR- Phenotype T-Cell Lymphoma with Complete Remission after Allogeneic Stem Cell Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.